library.onepin.app/follistatin-344 Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Research Peptide Not FDA-approved · investigational Controlled substance

Follistatin 344

Follistatin · FST-344 · FS-344

Research PeptideMyostatin Inhibitor

Follistatin 344 (FST344) is a recombinant form of the naturally occurring glycoprotein follistatin, which is a potent endogenous inhibitor of activins, myostatin, and other members of the TGF-beta superfamily. The 344 designation refers to the full-length 344-amino-acid isoform, which is the precursor form that can be processed into shorter tissue-specific variants (FST315 and FST288). Follistatin plays a critical role in regulating muscle growth, reproductive physiology, and tissue repair.,Myostatin (GDF-8) is the primary negative regulator of skeletal muscle mass, and its inhibition by follistatin leads to dramatic muscle hypertrophy in animal models. Natural mutations in the myostatin gene or elevated follistatin expression have been documented in exceptionally muscular animals (Belgian Blue cattle, whippet dogs) and in one documented human case. This has driven interest in follistatin as a potential therapeutic for muscle-wasting conditions and as a performance-enhancing agent.,Follistatin 344 is currently a research compound with no regulatory approval for human use. Gene therapy approaches using follistatin (delivered via AAV vectors) have entered clinical trials for muscular dystrophies, including Becker muscular dystrophy and inclusion body myositis, conducted by Nationwide Children's Hospital. Injectable recombinant follistatin 344 used in the peptide community has not been studied in formal clinical trials and its pharmacokinetics, optimal dosing, and safety profile in humans are not well characterized.

Quick Start
Route
Subcutaneous (SubQ)
Start low
100mcg
Frequency
daily
Timing
No specific requirement

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
100mcg · Subcutaneous (SubQ) · daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
100mcg
daily
Expert
Myostatin Inhibition Cycle
100 mcg · IM · Daily
animal study · Haidet et al. 2008 (Proc Natl Acad Sci U S A)
100 mcg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Binds and neutralizes myostatin (GDF-8), activin A, and activin B with high affinity, preventing them from activating their type II receptors (ActRIIA/ActRIIB). By sequestering myostatin, follistatin removes the primary brake on skeletal muscle growth, allowing the Akt/mTOR hypertrophy pathway to proceed unchecked.,Modulates the activin-FSH axis in reproductive physiology. By binding activin, follistatin reduces FSH secretion from the anterior pituitary, which can affect gonadal function. This reproductive effect is an important consideration for off-label use.,May promote satellite cell activation and muscle regeneration by reducing TGF-beta superfamily signaling that normally inhibits myogenic differentiation. Also implicated in reducing fibrosis in damaged tissues by antagonizing activin-driven fibrotic pathways.

Binds and neutralizes myostatin (GDF-8), activin A, and activin B with high affinity, preventing them from activating their type II receptors (ActRIIA/ActRIIB). By sequestering myostatin, follistatin removes the primary brake on skeletal muscle growth, allowing the Akt/mTOR hypertrophy pathway to proceed unchecked.,Modulates the activin-FSH axis in reproductive physiology. By binding activin, follistatin reduces FSH secretion from the anterior pituitary, which can affect gonadal function. This reproductive effect is an important consideration for off-label use.,May promote satellite cell activation and muscle regeneration by reducing TGF-beta superfamily signaling that normally inhibits myogenic differentiation. Also implicated in reducing fibrosis in damaged tissues by antagonizing activin-driven fibrotic pathways.

02

What to expect

Early
Days 1–7

Days 1-7: Circulating myostatin is being bound by exogenous follistatin. No visible or subjective muscle changes expected in the first week.

03

Evidence

HumanNo published trials
AnimalPresent
In-vitroPresent
2015A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy · Mendell JR, Sahenk Z, Al-Zaidy S, et al, Molecular Therapy ↗trial registry
2015Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy · Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR, Journal of Neuromuscular Diseases ↗peer reviewed
2004Myostatin mutation associated with gross muscle hypertrophy in a child · Schuelke M, Wagner KR, Stolz LE, et al, New England Journal of Medicine ↗case report
2009Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates · Kota J, Handy CR, Haidet AM, et al, Science Translational Medicine ↗peer reviewed
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

IpamorelinGH secretagogue supports body composition alongside myostatin inhibition. Non-overlapping mechanisms.
TesamorelinGHRH analog for GH axis support. Complementary body composition effects.
BPC-157Follistatin promotes muscle growth via myostatin inhibition while BPC-157 supports tissue repair and recovery. Complementary anabolic and recovery pathways.
TB-500Follistatin drives muscle hypertrophy, TB-500 enhances cell migration and tissue repair. Complementary for muscle building and recovery.

Keep separate

All compounds (syringe)Follistatin 344 is a large protein (~38kDa). Pin alone - do not mix in same syringe with other peptides. Risk of aggregation and loss of biological activity.
05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
Estimated hours for recombinant protein (exact data limited). Rapid renal clearance expected for the unmodified protein. Gene therapy delivery achieves sustained expression lasting months to years.
Peak · Tmax
~1-3 hours SubQ (estimated)
Elimination
~12-24 hours (recombinant protein, estimated)
Activity
12-24 hours (myostatin binding effects persist while protein is circulating)

Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 7-14 days. Avoid repeated freeze-thaw cycles. Sensitive to degradation.

06

Regulatory status

Research compound only. Not approved by the FDA or any regulatory agency for injectable human use. Gene therapy variants (AAV-follistatin) are in clinical trials for muscular dystrophies. Not a controlled substance but may violate anti-doping regulations (WADA prohibited list under gene doping/growth factors).

Put it to work

Calculate, log & track

Open Follistatin 344 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Follistatin 344 in the app →

Go deeper

The guide & community

The complete Follistatin 344 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community